NASDAQ:FBIOP Fortress Biotech (FBIOP) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free FBIOP Stock Alerts $13.82 +0.52 (+3.91%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$13.50▼$14.1550-Day Range$13.27▼$17.4352-Week Range$6.40▼$18.91Volume4,596 shsAverage Volume13,002 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield16.93%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Fortress Biotech alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Fortress Biotech Stock (NASDAQ:FBIOP)Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Read More FBIOP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBIOP Stock News HeadlinesApril 23, 2024 | seekingalpha.comFBIOP Fortress Biotech, Inc. 9.375% CUM PFD AMarch 28, 2024 | investorplace.comFBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q4 2023April 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 21, 2024 | finance.yahoo.comJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 18, 2024 | finance.yahoo.comCheckpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of DirectorsMarch 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fortress Biotech (FBIO) and Phreesia (PHR)February 22, 2024 | benzinga.comFortress Biotech Stock (NASDAQ:FBIO) Insider TradesFebruary 22, 2024 | benzinga.comFortress Biotech Stock (NASDAQ:FBIO), Short Interest ReportApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 17, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$3.06m On Fortress BiotechFebruary 13, 2024 | msn.comFortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 goes ex dividend tomorrowFebruary 2, 2024 | stockhouse.comLindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from SubsidiariesFebruary 2, 2024 | finance.yahoo.comLindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from SubsidiariesJanuary 3, 2024 | finance.yahoo.comFortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 3, 2024 | sg.finance.yahoo.comFortress Biotech Inc (CNB1.SG)December 29, 2023 | markets.businessinsider.comNasdaq Down Over 100 Points; Fortress Biotech Shares PlummetDecember 29, 2023 | marketwatch.comFortress Biotech Shares Drop After Offering Gets PricedDecember 29, 2023 | msn.comFortress Biotech drops on plans to issue 3.3M sharesDecember 29, 2023 | markets.businessinsider.comFortress Biotech Announces Pricing Of Registered Direct Offering - Quick FactsDecember 13, 2023 | finance.yahoo.comAnalysts Expect Breakeven For Fortress Biotech, Inc. (NASDAQ:FBIO) Before LongDecember 7, 2023 | msn.comOrganovo, Fortress Biotech among healthcare moversNovember 28, 2023 | morningstar.comFortress Biotech Inc FBIONovember 16, 2023 | finance.yahoo.comInsider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires Shares ...November 15, 2023 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 15, 2023 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Announces Closing of $10.0 Million Public OfferingNovember 14, 2023 | finance.yahoo.comFortress Biotech Announces Closing of $10.0 Million Public OfferingNovember 14, 2023 | finance.yahoo.comMustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsSee More Headlines Receive FBIOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 3/31 Dividend3/14/2024Dividend Payable3/31/2024Ex-Dividend for 4/30 Dividend4/12/2024Today4/26/2024Dividend Payable4/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:FBIOP CUSIPN/A CIK1429260 Webwww.fortressbiotech.com Phone781-652-4500FaxN/AEmployees187Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$84.51 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 69)Executive Chairman, President & CEO Comp: $942.78kMr. Michael S. Weiss Esq. (Age 58)Vice Chairman & Executive Vice Chairman of Strategic Development Comp: $167.92kMr. David Jin (Age 33)CFO & Head of Corporate Development Comp: $976.96kDr. George C. Avgerinos (Age 70)Senior Vice President of Biologics Operations Comp: $386.49kMr. Samuel BerryGeneral Counsel & Corporate SecretaryKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors FBIOP Stock Analysis - Frequently Asked Questions How have FBIOP shares performed in 2024? Fortress Biotech's stock was trading at $11.87 at the beginning of the year. Since then, FBIOP stock has increased by 16.4% and is now trading at $13.82. View the best growth stocks for 2024 here. Are investors shorting Fortress Biotech? Fortress Biotech saw a increase in short interest in April. As of April 15th, there was short interest totaling 9,500 shares, an increase of 97.9% from the March 31st total of 4,800 shares. Based on an average daily trading volume, of 12,800 shares, the days-to-cover ratio is currently 0.7 days. View Fortress Biotech's Short Interest. How often does Fortress Biotech pay dividends? What is the dividend yield for Fortress Biotech? Fortress Biotech declared a monthly dividend on Friday, April 12th. Shareholders of record on Monday, April 15th will be given a dividend of $0.1953 per share on Tuesday, April 30th. This represents a $2.34 dividend on an annualized basis and a dividend yield of 16.96%. The ex-dividend date of this dividend is Friday, April 12th. Read our dividend analysis for FBIOP. Is Fortress Biotech a good dividend stock? Fortress Biotech (NASDAQ:FBIOP) pays an annual dividend of $2.34 per share and currently has a dividend yield of 12.11%. FBIOP has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for FBIOP. How do I buy shares of Fortress Biotech? Shares of FBIOP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBIOP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.